Home > Insider Trading > Filing (0000899243-20-034339)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1703057	Abcellera Biologics Inc.	ABCL	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1834424	Tryn Stimart	C/O Abcellera Biologics Inc. 2215 Yukon Street Vancouver A1 V5Y 0A1	Chief Legal Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2020-12-15	250	$20.00	250	No	4	P	Direct
Common Shares	Acquisiton	2020-12-15	250	$20.00	250	No	4	P	Indirect	By spouse

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Indirect	By spouse

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Stock Option (right to buy)	Acquisiton	2020-10-29	850,000	$0.00	850,000	$2.41
Common Shares	Stock Option (right to buy)	Acquisiton	2020-12-10	190,800	$0.00	190,800	$20.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
850,000		2030-10-29	No	4	A	Direct
190,800		2030-12-10	No	4	A	Direct

Footnotes

On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.
The exercise price reported above was converted from the Canadian exercise price of CAD $3.08 using an exchange rate of CAD $1.27840 = US $1.00.
25% of the shares subject to such option vest and become exercisable on October 29, 2021 and the remainder of the shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
25% of the shares subject to such option vest and become exercisable on December 31, 2021 and the remainder of the shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.